Corticosteroids

May potentiate amphotericin B-induced hypokalemia, predisposing to cardiac dysfunction. Avoid concomitant use unless necessary; monitor serum electrolytes and cardiac function.

Intensified electrolyte depletion, particularly hypokalemia, may occur with concurrent use of corticosteroids and chlorothiazide.

Intensified electrolyte depletion, particularly hypokalemia, may occur when corticosteroids are given with chlorothiazide sodium.

Anticholinergic drugs in presence of increased intraocular pressure may be hazardous when taken concurrently with corticosteroids.

Expected to increase risk of immunosuppression; additive immune system effects must be considered with fingolimod coadministration.

Intensified electrolyte depletion, particularly hypokalemia may occur.

May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.

Should be tapered in Crohn's disease patients on chronic corticosteroids when starting natalizumab therapy due to increased infection risk.

Should be tapered in Crohn's disease patients on chronic corticosteroids when starting natalizumab therapy due to increased infection risk.

Barbiturates enhance metabolism of exogenous corticosteroids. Dose adjustment may be needed when adding or withdrawing phenobarbital.

Barbiturates enhance the metabolism of exogenous corticosteroids, requiring dosage adjustments when barbiturates are added or withdrawn.

Corticosteroids are associated with sodium and fluid retention; concurrent use with sodium chloride injection may increase risk of hypernatremia and volume overload.

Corticosteroids cause sodium and fluid retention; concomitant use may increase risk of hypernatremia and volume overload.

Avoid concomitant use due to increased risk of hypernatremia and volume overload. If unavoidable, closely monitor serum electrolytes and fluid balance.

Concurrent use with sodium phosphate may result in hypernatremia.

Corticosteroids may increase the risk of sodium and fluid retention when administered with 3% Sodium Chloride Injection. Caution must be exercised.

Corticosteroids produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Prolonged use of high-dose corticosteroids should be avoided if possible when using RETHYMIC due to immunosuppressive effects.

May produce hyperglycemia and lead to loss of glycemic control.

Intensified electrolyte depletion, particularly hypokalemia, may occur when used concurrently with hydrochlorothiazide.

Concurrent use may potentiate hypokalemia, which could predispose patient to cardiac dysfunction. Serum electrolytes and cardiac function should be closely monitored.

Corticosteroids used in triple-therapy regimens with basiliximab; no dose adjustment necessary. No increase in adverse reactions observed.

Withdrawal of corticosteroids in chronic aspirin users may result in salicylism. Corticosteroids enhance renal clearance of salicylates.

Functional antagonism exists; corticosteroids inhibit calcium absorption while calcitriol promotes it.

Functional antagonism exists; corticosteroids inhibit calcium absorption while calcitriol promotes it. Concurrent use requires monitoring.

Corticosteroids may suppress the response to the skin test. Pharmacologic doses may suppress response after two weeks of therapy through decreased monocytes and lymphocytes, particularly T-cells.

Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.

Corticosteroid regimen is required before ELEVIDYS administration. Patients should complete vaccinations at least 4 weeks prior to corticosteroid initiation due to immunosuppressive effects.

Topical corticosteroids suppress skin reactivity and should be discontinued at skin test site for at least 2-3 weeks before testing.

Caution must be exercised when administering 70% Dextrose Injection USP to patients receiving corticosteroids.

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Potentiate hypokalemic effects of epinephrine.

Potentiate the hypokalemic effects of epinephrine.

May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.

Corticosteroids may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Corticosteroids may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Corticosteroids may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Corticosteroids tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.

May increase plasma ammonia levels through protein breakdown. Monitor ammonia levels closely during concomitant use.

May cause electrolyte imbalance; caution advised with haloperidol decanoate as hypokalemia, hypomagnesemia, and hypocalcemia increase QT prolongation risk.

Drugs that cause electrolyte imbalance; caution advised due to risk of hypokalemia and hypomagnesemia which increase QT prolongation risk with haloperidol.

Concomitant usage may increase the risk of infection due to additive immune system effects.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be required.

May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

May decrease the blood glucose lowering effect. Dose adjustment and increased frequency of glucose monitoring may be required.

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Intensified electrolyte depletion, particularly hypokalemia.

Caution should be exercised when using together due to potential additive effects on bone loss.

Increased plasma concentrations reported with concomitant administration of oral contraceptives containing ethinyl estradiol.

Corticosteroids may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Regular use may acutely decrease bronchial responsiveness to methacholine chloride; may be continued during testing.

Methohexital may influence the metabolism of corticosteroids.

May increase risk of hypokalemia and increase salt and water retention.

May affect the results of the metyrapone test. Consider withdrawing if possible before testing.

May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and increased glucose monitoring may be required.

Immunosuppressant doses of corticosteroids used concomitantly with OCREVUS are expected to increase the risk of immunosuppression.

Immunosuppressant doses of corticosteroids with ocrelizumab are expected to increase the risk of immunosuppression. Consider risk of additive immune system effects when coadministering.

Concomitant use may increase the risk of infection due to additive immune system effects. Consider risk of additive immunosuppression when coadministering.

Adjust patient's vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. Certain vaccines are contraindicated for patients on substantially immunosuppressive steroid doses.

Adjust vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ZOLGENSMA infusion. Substantially immunosuppressive steroid doses (≥2 weeks of 20 mg or 2 mg/kg prednisone or equivalent) contraindicate certain live vaccines.

Caution must be exercised in the administration of Sodium Chloride Injection to patients receiving corticosteroids due to potential interaction.

Barbiturates enhance metabolism of exogenous corticosteroids. Dosage adjustments may be needed when barbiturates are added or withdrawn.

May increase risk of hypernatremia and volume overload. Monitor serum electrolytes, fluid balance, and acid-base balance if use cannot be avoided.

Concurrent use with sodium phosphate may result in hypernatremia.

Patients on corticosteroids may be at increased risk of hypoglycemia due to loss of counter-regulatory cortisol response; monitor for signs of hypoglycemia.

Corticosteroids decrease plasma salicylate levels; tapering doses may promote salicylism.

Corticosteroids decrease plasma salicylate levels; tapering doses may promote salicylism.

May potentiate LEUKINE's myeloproliferative effects. Use with caution and monitor frequently for clinical and laboratory signs of excess myeloproliferation.

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Concomitant use may increase risk of hypernatremia and volume overload. Avoid use; if unavoidable, monitor serum electrolytes, fluid balance, and acid-base balance.

Sodium-containing solutions should be administered with caution to patients receiving corticosteroids due to salt retention effects.

Concomitant use may increase risk of hypernatremia and volume overload. Monitor serum electrolytes, fluid balance and acid-base balance.

May cause protein catabolism and potentially increase plasma ammonia levels in patients with impaired urea formation ability.

May increase plasma ammonia level through breakdown of body protein; monitor ammonia levels closely.

Somatropin may alter clearance of corticosteroids metabolized by CYP450 liver enzymes; careful monitoring is advised.

Intensified electrolyte depletion, particularly hypokalemia, may occur.

Intensified electrolyte depletion, particularly hypokalemia, may occur.

GH may alter clearance of corticosteroids metabolized by CYP450 liver enzymes; monitor for potential interactions.

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Concurrent use may result in increased fluid retention; use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Concurrent use may result in increased fluid retention; use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Concurrent use with testosterone may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Concurrent use may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.

Increased risk of hypokalemia when used concomitantly with torsemide.

Concurrent use with hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalemia, though triamterene presence minimizes this effect.

Corticosteroids may depress or suppress reactivity to tuberculin test; reduced reactivity may persist for 5-6 weeks after discontinuation.

Concomitant use may increase risk of infection due to additive immune system effects. Consider risk of additive immunosuppression when co-administering.

Used concomitantly in approximately 40-50% of CD/UC subjects; safety and efficacy not adversely affected by combination.

Used concomitantly in approximately 40% of Crohn's disease and 50% of ulcerative colitis subjects. Use did not appear to influence overall safety or efficacy of ustekinumab.

Used concomitantly in approximately 40% and 50% of Crohn's disease and ulcerative colitis subjects respectively. Concomitant use did not appear to influence overall safety or efficacy of ustekinumab.

Used concomitantly in approximately 40% of Crohn's disease and 50% of ulcerative colitis subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Used concomitantly in approximately 40-50% of inflammatory bowel disease subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Used concomitantly in approximately 40-50% of Crohn's disease and ulcerative colitis subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Used concomitantly in ~40-50% of CD/UC subjects; did not appear to influence overall safety or efficacy of ustekinumab.

Administered concomitantly in clinical trials without evidence of clinically meaningful effect on belimumab pharmacokinetics.

No significant interactions observed with concurrent use of corticosteroids for up to 28 days in clinical trials.

Romiplostim may be used with corticosteroids as part of medical ITP therapy combination.